North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 1.410

-6.6%

Nov 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: andy harrison who wrote (24)	10/20/1996 12:05:00 PM
From: andy harrison	of 82

NVX had more good news last week. Dennis Kasper of the Harvard Medical School released intitial results of a 500 woman study for NVX's Group B Strep Vaccine (GBS). There is no vaccine for this disease on the market at all and no competition in sight. GBS affects 50,000 infants annually with a 15% death rate. Every woman of child bearing years is part of the target market. That figure is 150,000,000 women in the US alone. This is a huge number in that the world target market is absolutely enormous and adult vaccine often sell in the $40-50 price range. The factory that NVX bought from Cephalon will be used to manufacture the Strep and Menigitis vaccines. It is very important that NVX was able to buy this factory at this time as it will save them around $10 million dollars and will cut off about 3 years in time. By the way... The results of the 500 patient testing....very positve!!!!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next